SEC Form 4 · accession 0001179110-15-012247
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Renee D Gala
Officer — SVP, Chief Financial Officer
Period of report
Aug 13, 2015
Accepted (ET)
Aug 17, 2015 · 7:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 13, 2015 | P | 5,000 | $12.19 | A | 154,279 | D | |
| Ordinary SharesF2,F3 | Aug 17, 2015 | P | 5,000 | $12.16 | A | 161,177 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the weighted average purchase price per share for the open market purchase on August 13, 2015. The shares were purchased at prices ranging from $12.18 to $12.20 per share. Full information regarding the number of shares purchased at each price shall be provided upon request from the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F2Represents the weighted average purchase price per share for the open market purchase on August 17, 2015. The shares were purchased at prices ranging from $12.12 to $12.24 per share. Full information regarding the number of shares purchased at each price shall be provided upon request from the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3Includes 1,898 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2015.